ELders AT Ease Program (ELATE): A Cluster Randomised Controlled Trial Of A Sustainable And Scalable Mental Health Service For Australian Residential Aged Care Facilities
Funder
National Health and Medical Research Council
Funding Amount
$999,551.00
Summary
Elders living in residential facilities suffer significant levels of depression or anxiety. This study examines an innovative program to improve mental health of residents living in such facilities. The program involves counselling, staff training and family support. The study uses a cluster randomised controlled trial of facilities to evaluate the impact of ELATE: Elders at Ease Program” on residents’ psychological wellbeing, staff knowledge, family carer stress and, health care costs.
Improving Outcome after Stroke through Earlier Rehabilitation: The Very Early Rehabilitation Research Program. Stroke presents a major, growing global public health challenge accounting for 25% of all chronic disability. Treatments that reduce the burden of stroke are urgently needed, and early rehabilitation may significantly reduce chronic disability. A large, high quality, National Health and Medical Research Council funded clinical trial is at the heart of the A Very Early Rehabilitation Tri ....Improving Outcome after Stroke through Earlier Rehabilitation: The Very Early Rehabilitation Research Program. Stroke presents a major, growing global public health challenge accounting for 25% of all chronic disability. Treatments that reduce the burden of stroke are urgently needed, and early rehabilitation may significantly reduce chronic disability. A large, high quality, National Health and Medical Research Council funded clinical trial is at the heart of the A Very Early Rehabilitation Trial (AVERT) program. The trial tests whether a simple, rehabilitation intervention (early and intensive out of bed activity) results in fewer deaths and less disability for stroke sufferers and is cost effective. If effective the intervention could be adopted across different health services both here and overseas, reducing the global burden of stroke.Read moreRead less
Preclinical Development Of A Therapeutic Anticancer Antibody To C-Met
Funder
National Health and Medical Research Council
Funding Amount
$435,530.00
Summary
Many common cancers cannot be effectively treated. A range of these cancers (e.g. gastric and lung cancer) display the molecule c-Met on their cell surface. c-Met promotes tumour growth; therefore, blocking c-Met is a promising strategy for treating these cancers. However, no antibodies or drugs that target c-Met have been licensed. The therapeutics that are being developed to target c-Met all have considerable limitations. Thus, there is an opportunity to develop a 'best-in-class' therapeutic.
Developing methods for benefit measurement in health-related economic analyses and their use in selecting public health promotional programs. The program involves the creation, validation and use of a suite of instruments for evaluating outcomes of health promotional programs, including adult and childhood obesity, depression and smoking - areas that are universally recognised as being of importance for the Australian community. The program will provide multiple scoring algorithms for each of th ....Developing methods for benefit measurement in health-related economic analyses and their use in selecting public health promotional programs. The program involves the creation, validation and use of a suite of instruments for evaluating outcomes of health promotional programs, including adult and childhood obesity, depression and smoking - areas that are universally recognised as being of importance for the Australian community. The program will provide multiple scoring algorithms for each of the instruments in order to test the sensitivity of results to assumptions made about social values, and will produce Australian estimates of the person trade-off weights used in the Australian and Victorian Burden of Disease studies (which presently use Dutch PTO weights). Read moreRead less
A Centre For Research Excellence In Cerebral Palsy (CRE-CP)
Funder
National Health and Medical Research Council
Funding Amount
$2,622,042.00
Summary
Cerebral palsy is the most common physical disability in childhood. Our objective is to bring about a radical improvement in the treatment of individuals with cerebral palsy, both children and adults, and to determine better ways to assist their families. Emphasis will be placed on early detection of health issues and rigorous evaluation of management options. We will train more researchers and ensure that all the knowledge generated is made available to families and health care professionals.
An Integrated Approach For The Efffective Adoptive Immunotherapy Of Cancer
Funder
National Health and Medical Research Council
Funding Amount
$468,119.00
Summary
Killer T lymphocytes can penetrate tumors and their transfer into cancer patients has demonstrated some encouraging results, but this form of immunotherapy remain ineffective in most cancer patients. We propose to improve the tumor trafficking and anti-tumor activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells. The outcomes of this project will validate this novel approach for treatment of cancer patients.
Utilization Of Gene-engineered T Cells For Enhancing Cancer Immunotherapy
Funder
National Health and Medical Research Council
Funding Amount
$761,656.00
Summary
Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form of therapy and other approaches including vaccination remain ineffective in most cancer patients. In this project, we propose to improve the tumour trafficking and anti-tumour activities of killer cells by genetically engineering them with proteins that will enable them to recognise and destroy cancer cells, whilst minimizing toxicity to normal tissue.
New Strategies For Enhancing Chimeric Antigen Receptor (CAR) T Cell Therapy For Cancer
Funder
National Health and Medical Research Council
Funding Amount
$849,540.00
Summary
The role of the immune system in cancer is now recognised as highly important, highlighted by the success of immunotherapy in patients. Yet many patients fail to respond to this form of treatment due to low frequency of lymphocytes present at the tumor site. A new form of immunotherapy involving transfer of gene-modified lymphocytes is a potential way to overcome this problem. This project will explore new strategies to enhance the utility of this approach against blood and solid cancers.